Melvin L.K. Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology at National Cancer Centre Singapore, shared a post on LinkedIn:
“With the hype around Artificial Intelligence, some cynics have been cautious about the sustainability and funding of Big Machine in practice, especially in areas where AI is assistive to current workflows.
This may be one way where AI could support Precision Oncology in the clinic, and be transformative. ArteraAI is among the leaders in this field developing new diagnostics for Cancers that is now accessible to patients!
Glad to have contributed to this interview!”
More posts featuring Melvin L.K. Chua.